Literature DB >> 10521993

Mucosal and plasma prostaglandin E2 in ulcerative colitis.

A Wiercinska-Drapalo1, R Flisiak, D Prokopowicz.   

Abstract

BACKGROUND/AIMS: Despite extensive studies, the role of prostaglandins in the course of inflammatory bowel diseases and their possible usefulness as predictive indicators of inflammation, remain largely speculative. The aim of this study was to determine whether mucosal and plasma concentrations of prostaglandin E2 (PGE2) are affected by the clinical course and degree of colonic injury in patients with ulcerative colitis.
METHODOLOGY: PGE2 concentration was measured with an enzyme immunoassay (EIA) in biopsies of rectal mucosa and in the plasma of 38 patients with ulcerative colitis and 12 controls. Patients were divided into groups according to mild or severe clinical course of the disease, and with respect to scored endoscopical picture.
RESULTS: Ulcerative colitis resulted in an increase of mucosal and plasma concentrations of PGE2, that was significantly elevated in patients with a severe clinical course of the disease. These concentrations increased depending on degree of mucosal injury. A significant, positive correlation with endoscopical score regarding plasma and mucosal PGE2 concentration, as well as between them, was found.
CONCLUSIONS: Plasma and mucosal PGE2 rise simultaneously with degree of colonic injury. Because of a good correlation with mucosal injury and PGE2 content, measurement of plasma PGE2 could be considered as a possible surrogate marker of bowel inflammation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10521993

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  5 in total

Review 1.  New insights into the role of fatty acids in the pathogenesis and resolution of inflammatory bowel disease.

Authors:  Darla R Shores; David G Binion; Bruce A Freeman; Paul R S Baker
Journal:  Inflamm Bowel Dis       Date:  2010-12-03       Impact factor: 5.325

2.  The role of prostaglandin E2 (PGE 2) in toll-like receptor 4 (TLR4)-mediated colitis-associated neoplasia.

Authors:  Yasmin Hernandez; John Sotolongo; Keith Breglio; Daisy Conduah; Anli Chen; Ruliang Xu; David Hsu; Ryan Ungaro; Lory A Hayes; Cristhine Pastorini; Maria T Abreu; Masayuki Fukata
Journal:  BMC Gastroenterol       Date:  2010-07-16       Impact factor: 3.067

3.  Antagonizing arachidonic acid-derived eicosanoids reduces inflammatory Th17 and Th1 cell-mediated inflammation and colitis severity.

Authors:  Jennifer M Monk; Harmony F Turk; Yang-Yi Fan; Evelyn Callaway; Brad Weeks; Peiying Yang; David N McMurray; Robert S Chapkin
Journal:  Mediators Inflamm       Date:  2014-07-17       Impact factor: 4.711

4.  Nanoparticles Carrying NF-κB p65-Specific siRNA Alleviate Colitis in Mice by Attenuating NF-κB-Related Protein Expression and Pro-Inflammatory Cellular Mediator Secretion.

Authors:  Elena K Müller; Nataniel Białas; Matthias Epple; Ingrid Hilger
Journal:  Pharmaceutics       Date:  2022-02-15       Impact factor: 6.321

5.  Toll-like receptor 4 signaling integrates intestinal inflammation with tumorigenesis: lessons from the murine model of colitis-associated cancer.

Authors:  Yasmin Hernandez; John Sotolongo; Masayuki Fukata
Journal:  Cancers (Basel)       Date:  2011-08-02       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.